{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T15:13:27Z","timestamp":1771946007672,"version":"3.50.1"},"reference-count":46,"publisher":"Impact Journals, LLC","issue":"61","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,11,28]]},"DOI":"10.18632\/oncotarget.21528","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T20:55:38Z","timestamp":1507236938000},"page":"103077-103086","source":"Crossref","is-referenced-by-count":36,"title":["Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib"],"prefix":"10.18632","volume":"8","author":[{"given":"Alberto","family":"Lu\u00e9","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hospital Cl\u00ednico Universitario Lozano Blesa, 50009, Zaragoza, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria (IIS) Arag\u00f3n, 50009, Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Trinidad","family":"Serrano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Cl\u00ednico Universitario Lozano Blesa, 50009, Zaragoza, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria (IIS) Arag\u00f3n, 50009, Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Bustamante","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Universitario Cruces, Plaza de Cruces, 48903, Barakaldo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"I\u00f1arrairaegui","sequence":"additional","affiliation":[{"name":"Liver Unit, Clinica Universidad de Navarra-IDISNA, 31008, Pamplona, Spain"},{"name":"Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBEREHD), 31008, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Ignacio","family":"Arenas","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Universitario Donostia, Begiristain Doktorea Pasealekua, 20014, San Sebastian, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milagros","family":"Testillano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Universitario Cruces, Plaza de Cruces, 48903, Barakaldo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Lorente","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Cl\u00ednico Universitario Lozano Blesa, 50009, Zaragoza, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria (IIS) Arag\u00f3n, 50009, Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Gil","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Universitario Cruces, Plaza de Cruces, 48903, Barakaldo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"de la Torre","sequence":"additional","affiliation":[{"name":"Liver Unit, Clinica Universidad de Navarra-IDISNA, 31008, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Gomez","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Universitario Donostia, Begiristain Doktorea Pasealekua, 20014, San Sebastian, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[{"name":"Liver Unit, Clinica Universidad de Navarra-IDISNA, 31008, Pamplona, Spain"},{"name":"Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBEREHD), 31008, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Bruix","year":"2003","journal-title":"Lancet"},{"key":"2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","author":"European Association For The Study Of The Liver","year":"2012","journal-title":"J Hepatol"},{"key":"3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000348325","article-title":"Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90","volume":"84","author":"Poon","year":"2013","journal-title":"Oncology"},{"key":"4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Zeuzem","year":"2008","journal-title":"N Engl J Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Ross","year":"2017","journal-title":"Lancet"},{"key":"6","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/s-0034-1394143","article-title":"Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST","volume":"34","author":"Bruix","year":"2014","journal-title":"Semin Liver Dis"},{"key":"7","first-page":"348","article-title":"Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions","volume":"32","author":"Sangro","year":"2012","journal-title":"Semin Liver Dis"},{"key":"8","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.26586","article-title":"Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design","volume":"58","author":"Bruix","year":"2013","journal-title":"Hepatology"},{"key":"9","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-11-2175","article-title":"Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma","volume":"18","author":"Bruix","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1053\/j.gastro.2011.02.006","article-title":"Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma","volume":"140","author":"Newell","year":"2011","journal-title":"Gastroenterology"},{"key":"11","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.2009.25.9895","article-title":"Advanced hepatocellular carcinoma: which staging systems best predict prognosis?","volume":"28","author":"Abou-Alfa","year":"2010","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/j.1365-2036.2011.04823.x","article-title":"Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib","volume":"34","author":"Grunberger","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/1756283X15618129","article-title":"Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib","volume":"9","author":"Bolondi","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jhep.2014.03.030","article-title":"Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib","volume":"61","author":"Bruix","year":"2014","journal-title":"J Hepatol"},{"key":"15","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study","volume":"65","author":"Sanyal","year":"2016","journal-title":"J Hepatol"},{"key":"16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/SLA.0b013e3181a77e59","article-title":"Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma","volume":"250","author":"Emond","year":"2009","journal-title":"Ann Surg"},{"key":"17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/bjc.2013.346","article-title":"A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II, III colon cancer patients","volume":"109","author":"Gerger","year":"2013","journal-title":"Br J Cancer"},{"key":"18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5230\/jgc.2013.13.3.196","article-title":"Neutrophil-to-Lymphocyte Ratio in Prognosis of Gastric Cancer","volume":"13","author":"Demirkol","year":"2013","journal-title":"J Gastric Cancer"},{"key":"19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s10147-014-0672-8","article-title":"Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer?","volume":"20","author":"Coban","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"20","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2147\/OTT.S52501","article-title":"Combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma","volume":"6","author":"Liu","year":"2013","journal-title":"Onco Targets Ther"},{"key":"21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.juro.2011.10.026","article-title":"Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma","volume":"187","author":"Tachibana","year":"2012","journal-title":"J Urol"},{"key":"22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.suronc.2013.12.001","article-title":"A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours","volume":"23","author":"Morris","year":"2014","journal-title":"Surg Oncol"},{"key":"23","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ygyno.2014.01.026","article-title":"Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer","volume":"132","author":"Cramer","year":"2014","journal-title":"Gynecol Oncol"},{"key":"24","doi-asserted-by":"crossref","first-page":"e58184","DOI":"10.1371\/journal.pone.0058184","article-title":"Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"25","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/TP.0b013e3182a53f2b","article-title":"Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil\/lymphocyte ratio","volume":"96","author":"Maehara","year":"2013","journal-title":"Transplantation"},{"key":"26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/SLA.0b013e318297ad6b","article-title":"Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis","volume":"258","author":"Maehara","year":"2013","journal-title":"Ann Surg"},{"key":"27","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1245\/s10434-012-2639-1","article-title":"Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization","volume":"20","author":"Schmidt","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-2407-13-78","article-title":"Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma","volume":"13","author":"Lee","year":"2013","journal-title":"BMC Cancer"},{"key":"29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/jso.23448","article-title":"Neutrophil-to-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma: a Western perspective","volume":"109","author":"Gamblin","year":"2014","journal-title":"J Surg Oncol"},{"key":"30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2012.08.017","article-title":"Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment","volume":"58","author":"Maehara","year":"2013","journal-title":"J Hepatol"},{"key":"31","doi-asserted-by":"crossref","first-page":"8398","DOI":"10.3748\/wjg.v19.i45.8398","article-title":"Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation","volume":"19","author":"Yan","year":"2013","journal-title":"World J Gastroenterol"},{"key":"32","doi-asserted-by":"publisher","first-page":"45283","DOI":"10.18632\/oncotarget.9942","article-title":"Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies","volume":"7","author":"Guo","year":"2016","journal-title":"Oncotarget"},{"key":"33","doi-asserted-by":"publisher","first-page":"67142","DOI":"10.18632\/oncotarget.11565","article-title":"Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib","volume":"7","author":"Frassineti","year":"2016","journal-title":"Oncotarget"},{"key":"34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/hep.25950","article-title":"Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system","volume":"57","author":"Huo","year":"2013","journal-title":"Hepatology"},{"key":"35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/sj.bjc.6600466","article-title":"The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer","volume":"87","author":"Milroy","year":"2002","journal-title":"Br J Cancer"},{"key":"36","doi-asserted-by":"publisher","first-page":"14408","DOI":"10.18632\/oncotarget.14797","article-title":"Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma","volume":"8","author":"Lamar","year":"2017","journal-title":"Oncotarget"},{"key":"37","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.7314\/APJCP.2013.14.9.5527","article-title":"The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib","volume":"14","author":"Hu","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"38","doi-asserted-by":"crossref","first-page":"11057","DOI":"10.1007\/s13277-014-2360-8","article-title":"Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma","volume":"35","author":"Deng","year":"2014","journal-title":"Tumour Biol"},{"key":"39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Liang","year":"2009","journal-title":"Lancet Oncol"},{"key":"40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12032-014-0264-5","article-title":"Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib","volume":"31","author":"Sabbaga","year":"2014","journal-title":"Med Oncol"},{"key":"41","doi-asserted-by":"publisher","first-page":"36161","DOI":"10.18632\/oncotarget.15322","article-title":"Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib","volume":"8","author":"Sharma","year":"2017","journal-title":"Oncotarget"},{"key":"42","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.1097\/MD.0000000000000639","article-title":"Pretreatment neutrophil-lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma","volume":"94","author":"Wang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1471-2407-14-117","article-title":"Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis","volume":"14","author":"Liang","year":"2014","journal-title":"BMC Cancer"},{"key":"44","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2011.11.020","article-title":"Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis","volume":"56","author":"Mulcahy","year":"2012","journal-title":"J Hepatol"},{"key":"45","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma","volume":"379","author":"Bruix","year":"2012","journal-title":"Lancet"},{"key":"46","first-page":"751","article-title":"a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators","volume":"28","author":"A new prognostic system for hepatocellular carcinoma","year":"1998","journal-title":"Hepatology"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.21528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T18:20:02Z","timestamp":1596738002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.21528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":46,"journal-issue":{"issue":"61","published-print":{"date-parts":[[2017,11,28]]}},"alternative-id":["21528","29262546"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.21528","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,5]]}}}